Visceral Leishmaniasis (VL) Market Outlook

Thelansis’s “Visceral Leishmaniasis (VL) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Visceral Leishmaniasis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Visceral Leishmaniasis (VL) Overview

Visceral leishmaniasis (VL), also known as kala-azar, is the most severe and potentially fatal form of leishmaniasis, caused predominantly by Leishmania donovani in the Indian subcontinent and East Africa, and Leishmania infantum in Mediterranean and Latin American regions, transmitted through infected female phlebotomine sandfly bites. Leishmania amastigotes selectively parasitise mononuclear phagocytes of the reticuloendothelial system, including the spleen, liver, and bone marrow, evading lysosomal destruction through immune subversion and driving progressive organomegaly, haematopoietic suppression, and systemic inflammatory dysregulation. Patients present with prolonged irregular fever, massive splenomegaly, hepatomegaly, progressive pancytopenia, hypoalbuminaemia, hypergammaglobulinaemia, and profound cachexia, with untreated disease carrying near-universal mortality. Diagnosis integrates clinical findings with rK39 rapid diagnostic testing, tissue aspirate microscopy, and PCR-based parasite quantification. Liposomal amphotericin B is the globally preferred first-line therapy; single-dose regimens are highly efficacious on the Indian subcontinent but explicitly fail in East Africa, where different parasite susceptibility necessitates multi-dose or combination regimens including sodium stibogluconate plus paromomycin. HIV-coinfected patients require combination regimens regardless of geography given unacceptable relapse rates with single-dose approaches. Miltefosine provides a valuable oral alternative in eligible patients. Post-kala-azar dermal leishmaniasis represents the primary human transmission reservoir sustaining inter-epidemic transmission, making its identification and treatment the cornerstone of WHO elimination strategy. Prognosis is excellent with timely, region-appropriate treatment; vector control, active case detection, and PKDL surveillance are indispensable to achieving elimination targets.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)